期刊
CANCER
卷 121, 期 7, 页码 997-1007出版社
WILEY
DOI: 10.1002/cncr.28935
关键词
glioblastoma; bevacizumab; angiogenesis; vascular endothelial growth factor; malignant glioma
类别
资金
- Roche
- Merck Sharp and Dohme
- Genentech
- Genentech/Roche
- EMD Serono
- Merck/Schering
- Novartis
- Amgen
Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given recent clinical trials that have raised questions regarding its clinical effectiveness, the optimal timing of its use and the validity of endpoints, among other issues. In addition, uncertainty has recently arisen regarding the effects of bevacizumab on quality of life and neurocognitive function, two key clinical endpoints of unquestionable significance among glioblastoma patients. In this review, we highlight these controversies and other recent work related to bevacizumab for glioblastoma. Cancer 2015;121:997-1007. (c) 2014 American Cancer Society. Bevacizumab provides benefit for patients with recurrent glioblastoma. The results of recent trials have indicated that its role among newly diagnosed patients remains unclear.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据